StockData

Arcturus Therapeutics vs Viridian Therapeutics, Inc.\DE

ARCT and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARCT and VRDN compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 15 times as much as Arcturus Therapeutics ($3.4B against $227M).

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −76.0% for Arcturus Therapeutics).

Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −318% compared with −544% at Viridian Therapeutics, Inc.\DE.

Arcturus Therapeutics scores higher on the StockData Score (9 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARCTVRDN
Size and price
Market cap$227M$3.4B
Share price$7.97$30.06
Change, 1 year9.6%4.5%
Change, 5 years−80.0%64.3%
Beta (5Y)2.03−0.13
Employees111252
StockData Score
Total score9 (better)4
Valuation score2 (better)0
Growth score02 (better)
Performance score2 (better)1
Health score5 (better)1
Dividend score00
Valuation
P/S7.7× (better)47.9×
P/B1.3× (better)5.1×
FCF yield−32.1%−9.8% (better)
Fair value$8.83$8.47
Margin of safety9.8% (better)−255%
Growth
Revenue growth (TTM)−76.0%23220% (better)
Revenue growth, 5Y average53.8%132% (better)
Profitability
Operating margin−348% (better)−570%
Net margin−318% (better)−544%
FCF margin−248% (better)−471%
Return on equity−46.3% (better)−65.7%
Return on invested capital−1084%–
Financial health
Debt / equity0.00–
Interest coverage–−26.0×
Current ratio5.8816.95 (better)
Altman Z-score−1.442.65 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions87.9%120%
Held by insiders8.1%21.8%
Insider net buying, 12 months–$19.6M
Short interest, % of float20.7%19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.